Literature DB >> 3370932

Antimicrobial activity of U-76,252 (CS-807), a new orally administered cephalosporin ester, including recommendations for MIC quality control.

R N Jones1, A L Barry, M Pfaller, S D Allen, L W Ayers, P C Fuchs.   

Abstract

U-76,253A (R-3746), the active metabolite of the new cephalosporin ester, U-76,252 (CS-807), was tested against 4,742 fresh clinical isolates from four large medical centers. U-76,253A was very active against nearly all species of Enterobacteriaceae (87.7% inhibited at less than or equal to 4.0 micrograms/ml). Staphylococcus spp., and the streptococci. The U-76,253A spectrum was superior to the comparison orally administered cephalosporins (cephalexin, cephradine, cefaclor). Pseudomonas spp., Acinetobacter spp., and the enterococci were resistant to U-76,253A and the other tested drugs. Broth microdilution MIC quality control (QC) limits were established for U-76,253A in a multilaboratory investigation using a minimum of 125 MIC determinations per organism. The following MIC QC ranges were recommended; Escherichia coli (ATCC 25922) = 0.25-1.0 micrograms/ml, Staphylococcus aureus (ATCC 29213) = 2.0-4.0 micrograms/ml and Pseudomonas aeruginosa (ATCC 27853) = greater than 32 micrograms/ml.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370932     DOI: 10.1016/0732-8893(88)90063-6

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  6 in total

Review 1.  Microbiological conclusions.

Authors:  R N Jones
Journal:  Drugs       Date:  1991       Impact factor: 9.546

2.  Interpretive criteria of antimicrobial disk susceptibility tests with cefpodoxime.

Authors:  H Grimm
Journal:  Infection       Date:  1991 Sep-Oct       Impact factor: 3.553

3.  Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.

Authors:  J V St Peter; M T Borin; G S Hughes; J S Kelloway; B E Shapiro; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 4.  A review of the pharmacokinetics of cefpodoxime proxetil.

Authors:  M T Borin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

5.  Microbiological evaluation of cefpodoxime proxetil.

Authors:  B Wiedemann; E Luhmer; M T Zühlsdorf
Journal:  Drugs       Date:  1991       Impact factor: 9.546

6.  Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.

Authors:  C A Johnson; A Ateshkadi; S W Zimmerman; G S Hughes; W A Craig; P M Carey; M T Borin
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.